Clarity in Cell Line Development Commercial stable cell line development for biopharmaceutical production and gene therapy is a high value process which is inherently expensive and takes a significant amount of time. Solentim® has established itself over the past seven years as a significant leader and innovator of new products in the cell line development arena.
Our Cell Metric® product range of bright field imaging stations has a large global installed base of customers, and we are recognised as a leader for documenting proof of clonal origin for Master Cell Banks in filings to the regulators.
We have most recently introduced a second-generation single cell printing system called VIPS™, for customers that are looking for a simpler, more reliable alternative to FACS and limiting dilution
With the emergence of Covid-19 this year and the threat of other novel viruses looming on the horizon, now more than ever we need fast, efficient methods for generating novel vaccine candidates. These new methods could be developed as new ... Continued
Cell Line Development – A look at the evolution, new advances and future developments of this critical process step
In this written interview, Dr Ian Taylor, Chief Business Officer, Solentim, discusses the evolution of cell line development, new advances in technologies and workflows, and future advances. Our discussion includes improved imaging techniques, manual limiting dilution versus single cell seeding, ... Continued
Standard cell line development workflows include transfection followed by the screening of hundreds to thousands of clones, in an effort to find high producing clonal colonies that are stable and demonstrate specific attributes based on the product specifications. Some approaches ... Continued
Optimising outgrowth of clones following single cell cloning ensures more predictable and effective cell line development
Successful cell line development is critical to effective CHO cell based biomanufacturing. To accomplish this, companies must identify cell lines that have good manufacturing potential via clone selection. Clones that warrant further investigation are those that are stable, good producers, ... Continued
Informa’s Cell Line Development and Engineering conference last month was full of pharmaceutical companies and solutions providers sharing best practices, innovative solutions and emerging trends in Cell Line Development. I was pleased to attend the conference and wanted to share some ... Continued